We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

‘Glow-In-The-Dark’ Proteins to Help Diagnose Viral Diseases More Quickly and Easily

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: Proteins that glow bright blue or green could make disease diagnosis quicker and easier (Photo courtesy of Eindhoven University of Technology)
Image: Proteins that glow bright blue or green could make disease diagnosis quicker and easier (Photo courtesy of Eindhoven University of Technology)

Despite undergoing technological advancements, most diagnostic tests for viral diseases that are highly sensitive still involve complex techniques to prepare a sample or interpret the results, making it hard to administer these tests in point-of-care settings or in locations with limited resources. Now, a team of researchers has come up with a sensitive technique that analyzes viral nucleic acids in as little as 20 minutes and can be finished in one step using “glow-in-the-dark” proteins.

Bioluminescence is a scientific phenomenon caused by a chemical reaction involving the luciferase protein that creates the luminescent, glow-in-the-dark effect. The luciferase protein has been utilized in creating sensors that emit observable light when they detect their target, making them perfect for point-of-care testing. Nonetheless, these sensors lack the high levels of sensitivity required of a clinical diagnostic test. A gene-editing method known as CRISPR has shown promise in providing this ability, although it requires multiple steps and additional specialized instruments to detect low signals from a complex and noisy sample. So, researchers at Eindhoven University of Technology (Eindhoven, Netherlands) aimed to use CRISPR-related proteins, but combine them with a bioluminescence technique whose signal could be detected with only a digital camera.

In order to ensure that there were sufficient RNA or DNA samples for analysis, the scientists employed recombinase polymerase amplification (RPA), which is a straightforward technique that operates at a constant temperature of around 100 F. The researchers devised a new technique, LUNAS (luminescent nucleic acid sensor), that is comprised of two CRISPR/Cas9 proteins specific for different neighboring parts of a viral genome each have a distinct fragment of luciferase attached to them. Upon detecting the presence of a specific viral genome being tested, the two CRISPR/Cas9 proteins bind to the designated nucleic acid sections and are drawn close to one another, enabling the complete luciferase protein to form and shine blue light in the presence of a chemical substrate.

To take into account the depletion of the substrate, the researchers utilized a control reaction that radiated green light. The presence of a positive result was indicated by a tube that changed from green to blue. The RPA-LUNAS technique successfully detected SARS-CoV-2 RNA in clinical samples obtained from nasal swabs in just 20 minutes, even at concentrations as low as 200 copies per microliter. The researchers believe that the LUNAS assay holds immense potential for quickly and efficiently detecting various other viruses.

Related Links:
Eindhoven University of Technology 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.